7 or rosiglitazone8 therapy.

The NAVIGATOR Study Group: Effect of Nateglinide on the Incidence of Diabetes and Cardiovascular Events Individuals with impaired glucose tolerance are in increased risk for type 2 diabetes mellitus and cardiovascular disease1-3; therefore, treatments that might reduce the incidence of diabetes and associated cardiovascular death and disease are potentially important side effects of drugs .3 The chance of diabetes is reduced with lifestyle interventions that involve increasing exercise and reducing weight4-6 and with metformin,6 acarbose,7 or rosiglitazone8 therapy, but no trials to date have already been driven to consider cardiovascular outcomes.

Patients received proton-pump inhibitors until variceal eradication was accomplished. After eradication, endoscopic monitoring was performed at 1-month, 6-month, and 12-month intervals and annually then. If varices reappeared, further EBL sessions were initiated. Treatment failure was thought as one severe rebleeding episode , and vasoactive drugs then were administered until. If the portal-pressure gradient didn’t decrease to below 12 mm Hg, the stent was dilated to 10 mm. Suggestions revision was performed if there is clinical recurrence of portal hypertension or evidence of Ideas dysfunction on Doppler ultrasonography . Follow-up Follow-up visits were scheduled at one month, at three months, and every three months thereafter.